Australia-based BlinkLab leverages computer vision, artificial intelligence and machine learning by developing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD. The app turns the mobile phone into a medical device for an effortless way of conducting remote and rapid tests.
The BlinkLab Test aims to perform neurobehavioural testing free from facial instruments or other fixed location equipment. This AI-based platform is designed to be used at home or in similar environments, independently or with the assistance of a caregiver while following instructions from the mobile device application.
In collaboration with Princeton University in the US and Erasmus Medical Center in the Netherlands, Blinklab Test is initially developed as a prescription diagnostic aid to healthcare professionals (HCP). BlinkLab will need to complete a pivotal registrational study and subsequently apply for FDA registration and reimbursement for the tests.
Company Highlights
Australia-based BlinkLab is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed at Princeton University.The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.Once approved by the regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.
This BlinkLab is part of a paid investor education campaign.*
Click here to connect with BlinkLab to receive an Investor Presentation